RT Journal Article
SR Electronic
T1 Low systemic arterial compliance is associated with increased cardiovascular morbidity and mortality in aortic valve stenosis
JF Heart
JO Heart
FD BMJ Publishing Group Ltd and British Cardiovascular Society
SP 1507
OP 1514
DO 10.1136/heartjnl-2018-314386
VO 105
IS 19
A1 Edda Bahlmann
A1 Dana Cramariuc
A1 Sahrai Saeed
A1 John B Chambers
A1 Christoph A Nienaber
A1 Karl-Heinz Kuck
A1 Mai Tone Lønnebakken
A1 Eva Gerdts
YR 2019
UL http://heart.bmj.com/content/105/19/1507.abstract
AB Objective Lower systemic arterial compliance (SAC) is associated with increased cardiovascular morbidity and mortality in hypertension, but this has not been assessed in a prospective study in aortic valve stenosis (AS).Methods Data from 1641 patients (38% women) with initially asymptomatic mild-moderate AS enrolled in the Simvastatin and Ezetimibe in Aortic Stenosis study was used. Median follow-up was 4.3 years. SAC was assessed from Doppler stroke volume index to central pulse pressure ratio and considered low if ≤0.64 mL/m², corresponding to the lower tertile in the population. The association of SAC with outcome was assessed in Cox regression analysis and reported as HR and 95% CI.Results Low SAC at baseline was characterised by older age, female sex, hypertension, obesity, presence of a small aortic root, lower mean aortic gradient and more severe AS by effective aortic valve area (all p<0.01). In Cox regression analysis adjusting for factors, low SAC was associated with higher HRs for cardiovascular death (HR 2.13(95% CI 1.34 to 3.40) and all-cause mortality (HR 1.71(95% CI 1.23 to 2.38)), both p=0.001). The results did not change when systolic or diastolic blood pressure, other measures of AS severity or presence of discordantly graded AS were included in subsequent models. Presence of low SAC did not improve mortality prediction in reclassification analysis.Conclusions In patients with AS without diabetes and known cardiovascular disease, but a high prevalence of hypertension, low SAC was associated with higher cardiovascular and all-cause mortality independent of well-known prognosticators.Trial registration number NCT00092677; Post-results.